Target
UCP2
2 abstracts
Abstract
Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).Org: Universidad de Navarra, Madrid and Pamplona, Spain, Vall d'Hebron University Hospital, Barcelona, Spain, Istituto Nazionale Tumori, Fondazione ‘G. Pascale’, IRCCS, Naples, Italy, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, Hospital Universitario de Salamanca – Complejo Asistencial Universitario de Salamanca, Salamanca, Spain,
Abstract
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.Org: Universitätsklinikum Heidelberg, German Cancer Research Center, Sorbonne Université, AP-HP at Saint-Louis Hospital, ICM,